Activist Investor MAK Capital Reaches Cooperation Agreement with Evotec SE, Securing Board Nomination
Summary
Activist investor MAK Capital Fund LP, holding 7.1% of Evotec SE, has entered into a cooperation agreement with the company, leading to a board nomination and mutual voting commitments.
Key Events
-
Cooperation Agreement Signed
MAK Capital Fund LP and Evotec SE entered into a cooperation agreement on April 29, 2026, formalizing their relationship and future actions.
-
Board Nomination Secured
Evotec SE will nominate Dr. Wolfgang Hofmann as an independent member to the Supervisory Board at the upcoming Annual General Meeting on June 11, 2026.
-
Shareholder Voting Commitments
MAK Fund has agreed to customary voting and cooperation commitments, including supporting the board expansion to seven members and the three candidates nominated by the Issuer.
-
Increased Stake to 7.1%
MAK Capital Fund LP now beneficially owns 12,681,898 shares, representing approximately 7.1% of Evotec SE's outstanding shares, following recent purchases valued at approximately $7.38 million.
Analysis
This Schedule 13D/A filing confirms a significant development where activist investor MAK Capital Fund LP has reached a cooperation agreement with Evotec SE. The agreement, previously announced by the company in a 6-K filing on April 30, 2026, includes the nomination of Dr. Wolfgang Hofmann as an independent member to the Supervisory Board. This signals a constructive resolution between a major shareholder and the company, potentially avoiding future disputes and enhancing corporate governance. MAK Capital Fund LP also disclosed recent open market purchases totaling approximately $7.38 million, increasing their stake to 7.1%.
At the time of this filing, EVO was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.31 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.